Incyte Corporation (0J9P.L)
USD 59.6
(-3.84%)
USD 59.6
(-3.84%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.17 Billion USD | -9.23% |
| 2022 | -2.9 Billion USD | -43.67% |
| 2021 | -2.02 Billion USD | -36.87% |
| 2020 | -1.47 Billion USD | 17.04% |
| 2019 | -1.78 Billion USD | -55.41% |
| 2018 | -1.14 Billion USD | -30.96% |
| 2017 | -875.5 Million USD | -101467.05% |
| 2016 | -862 Thousand USD | -100.88% |
| 2015 | 98.45 Million USD | -58.43% |
| 2014 | 236.82 Million USD | 24.55% |
| 2013 | 190.13 Million USD | 77.67% |
| 2012 | 107.01 Million USD | 177.55% |
| 2011 | 38.55 Million USD | 130.98% |
| 2010 | -124.48 Million USD | -1761.8% |
| 2009 | -6.68 Million USD | -103.08% |
| 2008 | 217.4 Million USD | -21.71% |
| 2007 | 277.7 Million USD | -21.16% |
| 2006 | 352.24 Million USD | 6.62% |
| 2005 | 330.36 Million USD | 33.98% |
| 2004 | 246.58 Million USD | 78.57% |
| 2003 | 138.08 Million USD | -7.39% |
| 2002 | 149.1 Million USD | 9.74% |
| 2001 | 135.88 Million USD | 74.97% |
| 2000 | 77.65 Million USD | 342.68% |
| 1999 | -32 Million USD | 34.96% |
| 1998 | -49.2 Million USD | 1.6% |
| 1997 | -50 Million USD | -566.67% |
| 1996 | -7.5 Million USD | 27.18% |
| 1995 | -10.3 Million USD | -56.06% |
| 1994 | -6.6 Million USD | 55.1% |
| 1993 | -14.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.3 Billion USD | -4.21% |
| 2024 Q3 | -1.27 Billion USD | -33.47% |
| 2024 Q2 | -949.74 Million USD | 71.3% |
| 2023 Q3 | -3.19 Billion USD | -3.36% |
| 2023 Q2 | -3.09 Billion USD | -10.87% |
| 2023 Q1 | -2.78 Billion USD | 4.08% |
| 2023 FY | -3.17 Billion USD | -9.23% |
| 2023 Q4 | -3.17 Billion USD | 0.63% |
| 2022 Q2 | -2.38 Billion USD | -8.1% |
| 2022 Q1 | -2.2 Billion USD | -9.23% |
| 2022 FY | -2.9 Billion USD | -43.67% |
| 2022 Q4 | -2.9 Billion USD | -9.75% |
| 2022 Q3 | -2.64 Billion USD | -10.87% |
| 2021 Q3 | -1.95 Billion USD | -11.59% |
| 2021 Q4 | -2.02 Billion USD | -3.47% |
| 2021 FY | -2.02 Billion USD | -36.87% |
| 2021 Q1 | -1.63 Billion USD | -10.64% |
| 2021 Q2 | -1.75 Billion USD | -7.14% |
| 2020 FY | -1.47 Billion USD | 17.04% |
| 2020 Q1 | -982.82 Million USD | 44.84% |
| 2020 Q2 | -1.26 Billion USD | -28.71% |
| 2020 Q3 | -1.44 Billion USD | -13.86% |
| 2020 Q4 | -1.47 Billion USD | -2.63% |
| 2019 Q3 | -1.68 Billion USD | -23.28% |
| 2019 Q4 | -1.78 Billion USD | -5.81% |
| 2019 FY | -1.78 Billion USD | -55.41% |
| 2019 Q1 | -1.28 Billion USD | -11.82% |
| 2019 Q2 | -1.36 Billion USD | -6.54% |
| 2018 Q4 | -1.14 Billion USD | -5.45% |
| 2018 FY | -1.14 Billion USD | -30.96% |
| 2018 Q1 | -870.15 Million USD | 0.61% |
| 2018 Q2 | -903.94 Million USD | -3.88% |
| 2018 Q3 | -1.08 Billion USD | -20.28% |
| 2017 Q1 | -320.21 Million USD | -37048.38% |
| 2017 FY | -875.5 Million USD | -101467.05% |
| 2017 Q4 | -875.5 Million USD | 20.72% |
| 2017 Q3 | -1.1 Billion USD | -157.83% |
| 2017 Q2 | -428.32 Million USD | -33.76% |
| 2016 FY | -862 Thousand USD | -100.88% |
| 2016 Q1 | -29.97 Million USD | -130.44% |
| 2016 Q4 | -862 Thousand USD | -101.36% |
| 2016 Q3 | 63.33 Million USD | -57.16% |
| 2016 Q2 | 147.83 Million USD | 593.23% |
| 2015 Q2 | 220.28 Million USD | -20.11% |
| 2015 FY | 98.45 Million USD | -58.43% |
| 2015 Q4 | 98.45 Million USD | -44.73% |
| 2015 Q1 | 275.72 Million USD | 16.43% |
| 2015 Q3 | 178.13 Million USD | -19.14% |
| 2014 Q2 | 267.05 Million USD | 16.8% |
| 2014 Q4 | 236.82 Million USD | -20.88% |
| 2014 Q1 | 228.63 Million USD | 20.25% |
| 2014 Q3 | 299.3 Million USD | 12.08% |
| 2014 FY | 236.82 Million USD | 24.55% |
| 2013 Q4 | 190.13 Million USD | 323.73% |
| 2013 FY | 190.13 Million USD | 77.67% |
| 2013 Q1 | 71.69 Million USD | -33.0% |
| 2013 Q2 | -34.38 Million USD | -147.96% |
| 2013 Q3 | -84.98 Million USD | -147.16% |
| 2012 Q4 | 107.01 Million USD | 12.04% |
| 2012 FY | 107.01 Million USD | 177.55% |
| 2012 Q1 | 90.3 Million USD | 110.07% |
| 2012 Q2 | 66.5 Million USD | -26.36% |
| 2012 Q3 | 95.51 Million USD | 43.63% |
| 2011 Q2 | -54.54 Million USD | 30.9% |
| 2011 FY | 38.55 Million USD | 130.98% |
| 2011 Q4 | 42.98 Million USD | 2196.0% |
| 2011 Q3 | -2.05 Million USD | 96.24% |
| 2011 Q1 | -78.92 Million USD | 36.6% |
| 2010 Q1 | -127.04 Million USD | -1800.18% |
| 2010 FY | -124.48 Million USD | -1761.8% |
| 2010 Q4 | -124.48 Million USD | -23.57% |
| 2010 Q3 | -100.73 Million USD | 23.26% |
| 2010 Q2 | -131.26 Million USD | -3.32% |
| 2009 FY | -6.68 Million USD | -103.08% |
| 2009 Q1 | 259.57 Million USD | 19.4% |
| 2009 Q3 | 109.94 Million USD | -61.68% |
| 2009 Q2 | 286.93 Million USD | 10.54% |
| 2009 Q4 | -6.68 Million USD | -106.08% |
| 2008 Q4 | 217.4 Million USD | 16.82% |
| 2008 Q1 | 226.15 Million USD | -18.56% |
| 2008 Q2 | 256.56 Million USD | 13.45% |
| 2008 Q3 | 186.1 Million USD | -27.46% |
| 2008 FY | 217.4 Million USD | -21.71% |
| 2007 FY | 277.7 Million USD | -21.16% |
| 2007 Q1 | 352.9 Million USD | 0.19% |
| 2007 Q3 | 281.87 Million USD | -17.44% |
| 2007 Q4 | 277.7 Million USD | -1.48% |
| 2007 Q2 | 341.39 Million USD | -3.26% |
| 2006 Q3 | 344.81 Million USD | 10.26% |
| 2006 Q1 | 299.83 Million USD | -9.24% |
| 2006 Q4 | 352.24 Million USD | 2.16% |
| 2006 FY | 352.24 Million USD | 6.62% |
| 2006 Q2 | 312.73 Million USD | 4.3% |
| 2005 FY | 330.36 Million USD | 33.98% |
| 2005 Q1 | 273.85 Million USD | 11.06% |
| 2005 Q2 | 312.32 Million USD | 14.05% |
| 2005 Q3 | 292.72 Million USD | -6.28% |
| 2005 Q4 | 330.36 Million USD | 12.86% |
| 2004 FY | 246.58 Million USD | 78.57% |
| 2004 Q1 | 281.83 Million USD | 104.1% |
| 2004 Q2 | 264.64 Million USD | -6.1% |
| 2004 Q4 | 246.58 Million USD | -17.84% |
| 2004 Q3 | 300.12 Million USD | 13.41% |
| 2003 Q1 | 161.29 Million USD | 8.17% |
| 2003 FY | 138.08 Million USD | -7.39% |
| 2003 Q4 | 138.08 Million USD | -10.09% |
| 2003 Q3 | 153.58 Million USD | 2.52% |
| 2003 Q2 | 149.8 Million USD | -7.12% |
| 2002 Q4 | 149.1 Million USD | -4.67% |
| 2002 FY | 149.1 Million USD | 9.74% |
| 2002 Q1 | 79.98 Million USD | -41.14% |
| 2002 Q2 | 128.05 Million USD | 60.11% |
| 2002 Q3 | 156.4 Million USD | 22.14% |
| 2001 Q4 | 135.88 Million USD | 1.5% |
| 2001 FY | 135.88 Million USD | 74.97% |
| 2001 Q1 | 64.89 Million USD | -16.44% |
| 2001 Q2 | 115.07 Million USD | 77.33% |
| 2001 Q3 | 133.87 Million USD | 16.33% |
| 2000 Q2 | -234.82 Million USD | -7.76% |
| 2000 Q1 | -217.91 Million USD | -580.97% |
| 2000 FY | 77.65 Million USD | 342.68% |
| 2000 Q3 | -125.21 Million USD | 46.68% |
| 2000 Q4 | 77.65 Million USD | 162.02% |
| 1999 FY | -32 Million USD | 34.96% |
| 1999 Q1 | -83 Million USD | -68.7% |
| 1999 Q2 | -52.9 Million USD | 36.27% |
| 1999 Q3 | -41.2 Million USD | 22.12% |
| 1999 Q4 | -32 Million USD | 22.33% |
| 1998 Q4 | -49.2 Million USD | -8.37% |
| 1998 Q3 | -45.4 Million USD | -37.99% |
| 1998 FY | -49.2 Million USD | 1.6% |
| 1998 Q2 | -32.9 Million USD | 21.85% |
| 1998 Q1 | -42.1 Million USD | 15.8% |
| 1997 FY | -50 Million USD | -566.67% |
| 1997 Q1 | -7.9 Million USD | -5.33% |
| 1997 Q2 | -11.2 Million USD | -41.77% |
| 1997 Q3 | -51.2 Million USD | -357.14% |
| 1997 Q4 | -50 Million USD | 2.34% |
| 1996 Q4 | -7.5 Million USD | 61.54% |
| 1996 Q3 | -19.5 Million USD | -174.65% |
| 1996 Q2 | -7.1 Million USD | 42.74% |
| 1996 Q1 | -12.4 Million USD | -20.39% |
| 1996 FY | -7.5 Million USD | 27.18% |
| 1995 FY | -10.3 Million USD | -56.06% |
| 1995 Q2 | -7.2 Million USD | -26.32% |
| 1995 Q3 | -5.5 Million USD | 23.61% |
| 1995 Q4 | -10.3 Million USD | -87.27% |
| 1995 Q1 | -5.7 Million USD | 13.64% |
| 1994 FY | -6.6 Million USD | 55.1% |
| 1994 Q1 | -12.6 Million USD | 14.29% |
| 1994 Q2 | -9.3 Million USD | 26.19% |
| 1994 Q3 | -3.5 Million USD | 62.37% |
| 1994 Q4 | -6.6 Million USD | -88.57% |
| 1993 Q3 | -1.1 Million USD | 0.0% |
| 1993 Q4 | -14.7 Million USD | -1236.36% |
| 1993 FY | -14.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | -2984.078% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -10071.025% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 1703.054% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 10057.939% |
| bluebird bio, Inc. | 108.57 Million USD | 3024.436% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -35116.16% |
| Imunon, Inc. | -4.69 Million USD | -67465.536% |
| Editas Medicine, Inc. | -87.11 Million USD | -3544.668% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 124.699% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 251.342% |
| Myriad Genetics, Inc. | 88.1 Million USD | 3703.96% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 1890.8% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -9370.245% |
| Verastem, Inc. | -37.27 Million USD | -8417.327% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 138.556% |
| Waters Corporation | 1.96 Billion USD | 261.958% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 111.83% |
| Biogen Inc. | 6.28 Billion USD | 150.492% |
| Nektar Therapeutics | 210.24 Million USD | 1610.221% |
| Perrigo Company plc | 3.32 Billion USD | 195.575% |
| Dynavax Technologies Corporation | 106.63 Million USD | 3077.53% |
| Illumina, Inc. | 1.21 Billion USD | 361.539% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 45666.222% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | -2687.905% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 2288.569% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 44278.225% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 938.312% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -44619.563% |
| Evolus, Inc. | 63.7 Million USD | 5083.815% |
| Adicet Bio, Inc. | -142 Million USD | -2135.852% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -8527.022% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -11616.196% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 792.194% |
| FibroGen, Inc. | 56.76 Million USD | 5693.195% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 377.3% |
| OPKO Health, Inc. | 230.68 Million USD | 1476.386% |
| Homology Medicines, Inc. | 18.43 Million USD | 17321.289% |
| Geron Corporation | 14.76 Million USD | 21609.986% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 300.28% |
| Exelixis, Inc. | -73.05 Million USD | -4246.46% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -5752.051% |
| Anavex Life Sciences Corp. | -151.02 Million USD | -2002.374% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -2750.118% |
| Zoetis Inc. | 4.76 Billion USD | 166.676% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | -1488.967% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -31427.048% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 66.801% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -21688.972% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 401.164% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 427.877% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | -2244.97% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 329.933% |
| Blueprint Medicines Corporation | 702.83 Million USD | 551.754% |
| Insmed Incorporated | 721.62 Million USD | 539.995% |
| TG Therapeutics, Inc. | 17.86 Million USD | 17875.663% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 514.611% |